INTRODUCTION AND OBJECTIVES: Osteocalcin (OC) has been shown to regulate testosterone (T) production in mice and may offer a promising target for treatment of hypogonadal men. Yet, the relationship between OC and T has received little attention in human studies. Our objective was to evaluate the relationship between OC and T in a prospective cohort of men and to use an established rat model to assess the effect of T supplementation on OC levels.
METHODS: Men presenting to clinic for evaluation of hypogonadism were identified. Serum samples were assessed for total T, free T, sex hormone binding globulin (SHBG), bioavailable T, and OC. Similarly, T and OC levels were measured in Brown-Norway rats of varying ages. Testosterone levels were manipulated in the rat model using Translocator protein ligand (TSPO) to stimulate endogenous T production and silastic testosterone implants to increase exogenous T. Relationships between age, T and OC in humans and rats were evaluated using Pearson's correlation, fisher's transformation, and t-tests.
RESULTS: Ninety-two men (age 31-83y) were enrolled to participate in the study. The average total T and OC were 381.7 AE 195.7 and 49.2 AE 18.4, respectively. Total T and OC were positively correlated (R[ 0.57, 95% CI 0.39-0.71). Free T and OC also correlated (R[0.47, 95% CI 0.27-0.63). Men with total T 350 ng/dl or less had significantly lower OC levels than eugonadal men (13.1 vs. 19.1 ng/ml, p<0.01).
Thirty-six rats were included in the animal model. Aged rats were found to have lower total T (4.19 vs. 1.15 ng/ml, p< 0.01) and lower OC (1.81 vs. 0.97 ng/ml, p<0.01) than young rats. As in humans, T and OC were positively correlated (R[ 0.69, 95% CI 0.86-0.89). Aged rats were treated with a transporter protein (TSPO) ligand with daily injections for 10 days. This resulted in increase in total T by 43% and no significant change in OC. Young rats received silastic T implants for 8 weeks which increased serum T levels to >2000ng/ml. Interestingly, seminiferous tubule T concentration decreased by 80% and serum OC also showed a significant decline (2.19 vs 1.70, p [0.06).
CONCLUSIONS: OC levels correlate with total and free T in both rats and men. Increasing endogenous testosterone production and administration of exogenous testosterone did not affect osteocalcin levels.
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MP58-09 EFFECT OF TESTOSTERONE SUPPLEMENTATION THERAPY ON BONE HEALTH AMONGST MEN WITH TESTOSTERONE DEFICIENCY: A META-ANALYSIS OF RANDOMIZED PLACEBO-CONTROLLED TRIALS
Alexandra Berger*, Valary Raup, Ramy Abou Ghadya, Paul Bain, Martin Kathrins, Boston, MA INTRODUCTION AND OBJECTIVES: Men with testosterone deficiency (TD) are at an increased risk of developing osteoporosis, defined by low bone mineral density (BMD). Testosterone supplementation therapy (TST) has the potential to improve patients' BMD, preventing fractures. However, there is limited high-quality data to suggest TST measurably improves BMD in these men. We performed a meta-analysis of randomized, placebo-controlled trials (RCTs) to determine if TST is associated with significant increases in BMD.
METHODS: A systematic review using MEDLINE, Embase, Web of Science and Cochrane Central was performed. Search terms and methods are depicted in the PRISMA protocol flow diagram (Figure 1) . Only placebo-controlled RCTs of TST in men with TD were included. TD was defined as morning T <[12.1 nmol/L (<[300 ng/dL) or free T <[310 pmol/L. Minimum treatment was 12 weeks. Our primary outcome was DEXA-determined BMD in any anatomic location. Independent extraction of articles was performed by 2 authors. Meta-analysis was performed with RevMan 5.3 using weighted data and a random effects model, due to clinical heterogeneity.
RESULTS: TST formulation was heterogenous and included gel (3, n[252), intramuscular (2, n[82), capsule (1, n[126) and patch (1, n[39) . Patients received TST for a mean 33.17 weeks. There were 6 RCTs for femoral neck (n[461), 7 RCTs for lumbar (n[498) and 5 RCTs for total hip BMD (n[455) meeting our inclusion criteria. There was a significant association of TST with increase in femoral neck BMD compared to placebo (Standardized mean difference [SMD] 0.24, 95% CI 0.06-0.43) (Figure 2 ). There was no significant association of TST Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e855
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